Secondary prevention and lipid lowering: results and implications.
In a secondary prevention trial conducted by the National Heart, Lung, and Blood Institute, the effect of lipid lowering by drug intervention on the progression of existing coronary artery disease (CAD) was evaluated in type II hyperlipidemic patients. This first randomized, secondary prevention trial compared the effect of cholestyramine and diet with that of placebo and diet in 143 patients over a 5-year period. End points evaluated were progression or regression of CAD, as demonstrated by angiographic changes compared with baseline angiograms. The cholestyramine-treated group demonstrated a significant reduction in total cholesterol and in low-density lipoprotein cholesterol (LDL) levels as compared with placebo, and an 8% increase in high-density lipoprotein cholesterol (HDL). A statistically significant result supporting the use of cholestyramine treatment was found in one category of CAD progression.
D000790:Angiocardiography; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002792:Cholestyramine Resin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000517:prevention & control*; D004032:Diet; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000150:complications*; D008055:Lipids / Q000097:blood*; D008297:Male; D009316:National Institutes of Health (U.S.); D011897:Random Allocation; D014481:United States
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids; D002792:Cholestyramine Resin; D002784:Cholesterol